September 15, 2026 · Phase 2 readout
BHVN Phase 2 readout: a neutral outcome, -2.4%
On September 15, 2026, Taldefgrobep Alfa — Biohaven Pharmaceutical Holding Company Ltd. (Obesity) reached its Phase 2 readout. The result was a neutral outcome, and the stock moved -2.4% in the window around the event. It had already run -13.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$12.64
1d before
$12.34
Event day
$12.02
1d after
$13.62
5d after
Our prediction vs. the result
CatalystAlert called this one up (+6.3% expected); the stock actually moved -2.4%. Model confidence at the time: 60%.
See the full scored track recordPre-catalyst setup
-13.2%
30-day run-up
9910%
30-day volatility
0.5×
volume spike